Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Confo Therapeutics Enters Collaborative Agreement with Regeneron
Details : The agreement will leverage Confo’s expertise in addressing two GPCR targets for which functional antibodies are needed. Confo’s ConfoBody-based technology platform aims to overcome the limitations of drug discovery on GPCRs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 30, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration